drugset / Trial / NCT07184866

Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial

NCT07184866

Not yet recruiting 110 enrolled Institute of Liver and Biliary Sciences, India
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is testing whether Vitamin C can help improve kidney function and survival in very sick patients with liver disease. Patients with acute-on-chronic liver failure (ACLF) often develop serious infections that can lead to septic shock and kidney injury, which are major causes of death. In this randomized controlled trial, patients with ACLF and septic shock will be assigned to receive either: 1. Standard medical treatment alone, or 2. Standard medical treatment plus intravenous Vitamin C. Vitamin C is a safe, inexpensive antioxidant that may reduce inflammation, improve circulation, and protect the kidneys. The study will compare how well patients recover from septic shock and kidney injury in the two groups. Blood and urine samples will also be collected to look for biological markers that can predict outcomes.

Timeline

Start
2026-04
Primary completion
2027-07
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 25 mg/kg Intravenous

Indications